Most random gene expression signatures are significantly associated with breast cancer outcome

PLoS Computational Biology

Volumn 7, Issue 10, 2011, Pages

  Venet, David ^a   Dumont, Jacques E ^a   Detours, Vincent ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DISEASES; PURGING;

BIOLOGICAL MECHANISMS; BREAST CANCER; GENE EXPRESSION SIGNATURES; GENES EXPRESSION; HUMAN BREAST CANCER; HUMAN CANCER; HUMAN DISEASE; IN-VITRO MODELS; MEDICAL RESEARCH; RANDOM GENES;

GENE EXPRESSION;

CYCLINE; TRANSCRIPTOME; TUMOR MARKER;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC MARKER; HAZARD RATIO; HUMAN; METAGENOMICS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN GENE; SKIN FIBROBLAST; ANIMAL; BREAST TUMOR; CARCINOMA; EPIDEMIOLOGY; FEMALE; GENETICS;

ANIMALIA; MUS;

ANIMALS; BREAST NEOPLASMS; CARCINOMA; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80055090025     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002240     Document Type: Article

References (68)

1. Sotiriou C, Pusztai L, (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800 doi:10.1056/NEJMra0801289.
2. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009 doi:10.1056/NEJMoa021967.
3. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826 doi:10.1056/NEJMoa041588.
4. Pawitan Y, Bjöhle J, Amler L, Borg A-L, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964 doi:10.1186/bcr1325.
5. Korkola JE, Blaveri E, DeVries S, Moore DH, Hwang ES, et al. (2007) Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. BMC Cancer 7: 61 doi:10.1186/1471-2407-7-61.
6. Dai H, van't Veer L, Lamb J, He YD, Mao M, et al. (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65: 4059-4066 doi:10.1158/0008-5472.CAN-04-3953.
7. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65 doi:10.1186/bcr2124.
8. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158-5165 doi:10.1158/1078-0432.CCR-07-4756.
9. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G, (2008) A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24: 2200-2208 doi:10.1093/bioinformatics/btn374.
10. Ma X-J, Salunga R, Tuggle JT, Gaudet J, Enright E, et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100: 5974-5979 doi:10.1073/pnas.0931261100.
11. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301 doi:10.1158/0008-5472.CAN-05-4414.
12. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272 doi:10.1093/jnci/djj052.
13. Glinsky GV, Berezovska O, Glinskii AB, (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521 doi:10.1172/JCI23412.
14. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507 doi:10.1038/ng.127.
15. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2: 333-344 doi:10.1016/j.stem.2008.02.009.
16. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z, (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048 doi:10.1038/ng1861.
17. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2: E7 doi:10.1371/journal.pbio.0020007.
18. Chang HY, Nuyten DSA, Sneddon JB, Hastie T, Tibshirani R, et al. (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sc U S A 102: 3738-3743 doi:10.1073/pnas.0409462102.
19. Chi J-T, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47 doi:10.1371/journal.pmed.0030047.
20. Buffa FM, Harris AL, West CM, Miller CJ, (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102: 428-435 doi:10.1038/sj.bjc.6605450.
21. West RB, Nuyten DSA, Subramanian S, Nielsen TO, Corless CL, et al. (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3: e187 doi:10.1371/journal.pbio.0030187.
22. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, et al. (2010) Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 107: 15449-15454 doi:10.1073/pnas.1004900107.
23. Welm AL, Sneddon JB, Taylor C, Nuyten DSA, van de Vijver MJ, et al. (2007) The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A 104: 7570-7575 doi:10.1073/pnas.0702095104.
24. Buess M, Nuyten DSA, Hastie T, Nielsen T, Pesich R, et al. (2007) Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. Genome Biol 8: R191 doi:10.1186/gb-2007-8-9-r191.
25. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555 doi:10.1073/pnas.0506230102.
26. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, et al. (2008) Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28: 5605-5620 doi:10.1128/MCB.00787-08.
27. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She Q-B, et al. (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104: 7564-7569 doi:10.1073/pnas.0702507104.
28. Hallstrom TC, Mori S, Nevins JR, (2008) An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13: 11-22 doi:10.1016/j.ccr.2007.11.031.
29. Crawford NPS, Alsarraj J, Lukes L, Walker RC, Officewala JS, et al. (2008) Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci U S A 105: 6380-6385 doi:10.1073/pnas.0710331105.
30. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, et al. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137: 1032-1046 doi:10.1016/j.cell.2009.03.047.
31. Pei X-H, Bai F, Smith MD, Usary J, Fan C, et al. (2009) CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell 15: 389-401 doi:10.1016/j.ccr.2009.03.004.
32. Hua S, Kittler R, White KP, (2009) Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137: 1259-1271 doi:10.1016/j.cell.2009.04.043.
33. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, et al. (2009) Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28: 2796-2805 doi:10.1038/onc.2009.139.
34. Wong DJ, Nuyten DSA, Regev A, Lin M, Adler AS, et al. (2008) Revealing targeted therapy for human cancer by gene module maps. Cancer Res 68: 369-378 doi:10.1158/0008-5472.CAN-07-0382.
35. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560-569 doi:10.1056/NEJMoa052933.
36. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, et al. (2008) Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9: 394 doi:10.1186/1471-2164-9-394.
37. Mosley JD, Keri RA, (2008) Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics 1: 11 doi:10.1186/1755-8794-1-11.
38. Bloom HJ, Richardson WW, (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377.
39. Tubiana M, Pejovic MJ, Renaud A, Contesso G, Chavaudra N, et al. (1981) Kinetic parameters and the course of the disease in breast cancer. Cancer 47: 937-943 doi:10.1002/1097-0142(19810301)47:5&937::AID-CNCR2820470520>3.0.CO;2-6.
40. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
41. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123: 725-731 doi:10.1007/s10549-009-0674-9.
42. Ringnér M, Fredlund E, Häkkinen J, Borg A, Staaf J, (2011) GOBO: Gene Expression-Based Outcome for Breast Cancer Online. PLoS ONE 6: e17911 doi:10.1371/journal.pone.0017911.
43. Hayashi T, Urayama O, Kawai K, Hayashi K, Iwanaga S, et al. (2006) Laughter regulates gene expression in patients with type 2 diabetes. Psychother Psychosom 75: 62-65 doi:10.1159/000089228.
44. Rinn JL, Bondre C, Gladstone HB, Brown PO, Chang HY, (2006) Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet 2: e119 doi:10.1371/journal.pgen.0020119.
45. Krishnan V, Han M-H, Graham DL, Berton O, Renthal W, et al. (2007) Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131: 391-404 doi:10.1016/j.cell.2007.09.018.
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550 doi:10.1073/pnas.0506580102.
47. Storey JD, Tibshirani R, (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445 doi:10.1073/pnas.1530509100.
48. Ein-Dor L, Kela I, Getz G, Givol D, Domany E, (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171-178 doi:10.1093/bioinformatics/bth469.
49. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, et al. (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13: 1977-2000 doi:10.1091/mbc.02-02-0030.
50. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, et al. (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96: 9212-9217.
51. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752 doi:10.1038/35021093.
52. Whitfield ML, George LK, Grant GD, Perou CM, (2006) Common markers of proliferation. Nat Rev Cancer 6: 99-106 doi:10.1038/nrc1802.
53. Moldovan G-L, Pfander B, Jentsch S, (2007) PCNA, the maestro of the replication fork. Cell 129: 665-679 doi:10.1016/j.cell.2007.05.003.
54. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, et al. (2005) Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 86: 127-141 doi:10.1016/j.ygeno.2005.04.008.
55. Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96 doi:10.1186/1471-2164-7-96.
56. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246 doi:10.1200/JCO.2006.07.1522.
57. Ramaswamy S, Ross KN, Lander ES, Golub TR, (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54 doi:10.1038/ng1060.
58. Reuter JA, Ortiz-Urda S, Kretz M, Garcia J, Scholl FA, et al. (2009) Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. Cancer Cell 15: 477-488 doi:10.1016/j.ccr.2009.04.002.
59. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, et al. (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15: 9-20 doi:10.1016/j.ccr.2008.11.013.
60. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, et al. (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67: 10669-10676 doi:10.1158/0008-5472.CAN-07-0539.
61. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413 doi:10.1158/0008-5472.CAN-07-5206.
62. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10: R93 doi:10.1186/bcr2192.
63. Teschendorff AE, Caldas C, (2008) A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 10: R73 doi:10.1186/bcr2138.
64. Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, et al. (2010) Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 10: 604 doi:10.1186/1471-2407-10-604.
65. Haibe-Kains B, Desmedt C, Rothé F, Piccart M, Sotiriou C, et al. (2010) A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol 11: R18 doi:10.1186/gb-2010-11-2-r18.
66. R Development Core Team (n.d.) R: A Language and Environment for Statistical Computing. 1 ISBN 3-900051-07-0.
67. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80 doi:10.1186/gb-2004-5-10-r80.
68. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F, (2004) A model-based background adjustment for oligonucleotide expression arrays. J Amer Statistical Assoc 99: 909-917.